Wish to keep on prime of the science and politics driving biotech at this time? Join to get our biotech e-newsletter in your inbox.
At present we speak about how biopharma plans to harness AI for medical trial design, why two consultants suppose Medicare must cowl the pricey GLP-1 medication, and what information from Roivant means for its enterprise technique.
The necessity-to-know this morning:
- Danish drugmaker Genmab stated it could purchase ProfoundBio for $1.8 billion in money, the most recent in a string of offers tied to the booming discipline of antibody-drug conjugate therapies for most cancers.
- Oruka Therapeutics is going public via a reverse merger with ARCA Biopharma. Oruka is growing long-lasting antibodies that focus on IL-23 and IL-17 for the remedy of continual pores and skin situations like psoriasis. Concurrent with the merger, Oruka raised $275 million through a PIPE with a syndicate of well being care funding funds.
- Diaganol Therapeutics launched with $128 million in new funding to develop a brand new class of antibody medicines that activate, relatively than block, cell-signaling pathways to deal with extreme ailments.
How AI might be utilized in biopharma medical trials
Biopharma corporations are more and more turning to the startups that use synthetic intelligence to investigate knowledge from previous medical trials, genomic knowledge banks, and different well being information to foretell how therapies would possibly work. The calculus right here is to assist optimize medical trials — serving to choose which sufferers could be extra probably to reply to a given remedy, or to even create surrogate trial contributors referred to as digital twins.
For instance, final yr AstraZeneca and Bayer started working with the Toronto-based Altis Labs to check how digital twins would possibly reply in placebo arms of early-stage drug testing. One other startup, Nucleai, makes use of AI to map out the relationships between most cancers cells, wholesome cells, and proteins, pits it in opposition to previous medical knowledge, and determines which sufferers would possibly reply to experimental therapies.
“That is actually the place the business will go,” one investor on this house informed STAT. “We take a look at a future that’s extra digital, is extra computerized, and AI is simply one other software to do it higher.”
Learn extra.
What the Roivant information means for its enterprise mannequin
Roivants’s eye drug brepocitinib, which it licensed from Pfizer, just lately learn out in a small research. The corporate additionally introduced that it’ll purchase again $1.5 billion in inventory. These two bits of reports make us ask the query: Will the corporate’s strategy, which is to license shelved experimental medication from massive companies and additional develop them, work?
“Look, I believe the reality is, there are pharma corporations that, out of worry of wanting silly, don’t out license or associate their medication,” Roivant CEO Matt Gline informed STAT. “They only stick them in a bin someplace.”
However corporations like Pfizer, he stated, “take a principled stance that if there’s one thing that might profit sufferers, they may wish to maximize the footprint.” And that’s why he believes the Roivant strategy may assist larger pharma corporations ship extra worth to buyers.
Learn extra.
New knowledge on liquid biopsy for colorectal most cancers detection nonetheless underwhelms
A take a look at Freenome’s data on its colorectal most cancers liquid biopsy take a look at means that blood-based checks gained’t be stopping most cancers — however relatively catching it at later phases.
Freenome’s trial confirmed that their blood-based display screen has a 79.2% sensitivity in detecting colorectal most cancers throughout all phases. Damaged down, that’s a 57.1% sensitivity for detecting cancers at stage 1, 100% sensitivity at stage 2, 82.4% sensitivity at stage 3, and 100% sensitivity at stage 4. The outcomes path noticeably behind Guardant’s blood-based colorectal most cancers take a look at, which additionally confirmed a low sensitivity for detecting stage 1 cancers at 65% however 100% sensitivity for phases 2 by 4. That means that stool-based colorectal most cancers screenings and screening colonoscopy will stay the easiest way to catch cancers on the earliest phases or at precancerous phases.
Like Guardant, Freenome’s take a look at seems to solely be capable of reliably detect issues as soon as sufferers have already got colorectal most cancers. The efficiency for detecting precancerous polyps ranged at a very dismal 12.5% to 29% sensitivity, relying on the kind of polyp. Meaning for sufferers who hope that colorectal most cancers screening will assist them stop tumors earlier than they really type, liquid biopsies as they at present are gained’t swimsuit their preferences.
The monetary upside of Medicare overlaying GLP-1 medication
If Medicare lined weight problems medication like Zepbound and Wegovy, the U.S. may finally save billions of {dollars}, opine two well being coverage consultants at USC. They modeled the affect of GLP-1 medication — and located that estimates that they might financially cripple Medicare are “alarmist,” since competitors will rapidly drive down the costs of those medication. Take the hepatitis C drug Sovaldi: Though it was listed for $84,000, costing $1,000 per capsule, generic variations now promote for $69.
“GLP-1 medication current a historic alternative to create worth for individuals with weight problems, their households, and the nation so long as society can successfully share them throughout the well being care market,” they write.
Learn extra.
Acorda goes bankrupt, sells belongings to Merz for $180 million
Acorda Therapeutics, which makes medication to enhance to enhance neurological operate in ailments like Parkinson’s and a number of sclerosis, simply filed for chapter. It’s going to promote its belongings to Germany’s Merz Therapeutics for $185 million.
The New York-based firm has been struggling for years, thanks largely to competitors from generic drug makers and decrease gross sales than anticipated, FiercePharma writes. For instance, its Parkinson’s drug Inbrija was authorised in 2018 for Parkinson’s, and peak gross sales have been projected to be $800 million. But in 2022, international gross sales have been a mere $30.9 million.
Extra reads
- U.S. takes subsequent step in Medicare drug worth negotiations with pharmaceutical corporations, Reuters
- AbbVie commits to ‘making the large bets’ in new company marketing campaign, Endpoints
- J&J targets uncommon maternal-fetal ailments: ‘We’re going for this. Nobody else has,’ FierceBiotech